Renal Cancer - Results from #1220

A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy. November 10, 2022

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. November 10, 2022

A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma. November 9, 2022

3D renal model for surgical planning of partial nephrectomy: A way to improve surgical outcomes. November 9, 2022

The incidence and risk factors of chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. November 8, 2022

IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time. November 7, 2022

A novel prognostic model based on six methylation-driven genes predicts overall survival for patients with clear cell renal cell carcinoma. November 7, 2022

Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. November 7, 2022

Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential VHL Mutations Underlie Multifocal ccRCC. November 4, 2022

Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96). November 4, 2022

Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy. November 3, 2022

The significance of CD14 in clear cell renal cell carcinoma progression and survival prognosis. November 3, 2022

Imaging of pediatric renal tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper focused on Wilms tumor and nephrogenic rests. November 2, 2022

Partial Nephrectomy for T1b/T2 Renal Mass: An Added Shift from Radical Nephrectomy. November 2, 2022

Patient-Specific Mathematical Model of the Clear Cell Renal Cell Carcinoma Microenvironment. November 1, 2022

Diagnostic Performance of Contrast-Enhanced Ultrasound in the Evaluation of Small Renal Masses: A Systematic Review and Meta-Analysis. November 1, 2022

Treatment of Refractory Metastatic Renal Cell Carcinoma. November 1, 2022

Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. October 31, 2022

An external validation of the nocera nomogram: Predicting non-organ confined stage of ≥pT3 in cT1 clear cell renal cell carcinoma. October 31, 2022

Can microRNAs be utilized as tumor markers for recurrence following nephrectomy in renal cell carcinoma patients? A meta-analysis provides the answer. October 28, 2022

Page 62 of 456